QL Bio, a Beijing-based proteomics testing company, has reportedly secured tens of millions of renminbi in its inaugural funding round, which was exclusively led by Delian Capital. The capital raised will be directed towards enhancing QL Bio’s “one-stop proteomics platform” and advancing the discovery and clinical application of protein biomarkers.
Upgrading the One-Stop Proteomics Platform
The funds will be instrumental in upgrading QL Bio’s next-generation proteomics technology platform, which operates across various fields including blood, secretions, tissue sectioning, and single cell analysis. The platform is recognized for its full automation, micro detection capabilities, high-depth coverage, and accurate quantification features, making it a valuable tool in the field of proteomics.
Advancing Protein Biomarker Discovery and Clinical Translation
With the investment, QL Bio is poised to accelerate the discovery of protein biomarkers and their translation into clinical practice. This advancement is crucial for the development of personalized medicine and the enhancement of diagnostic and therapeutic approaches.-Fineline Info & Tech
